HC Wainwright Reiterates “Buy” Rating for Femasys (NASDAQ:FEMY)

Femasys (NASDAQ:FEMY)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, Chardan Capital dropped their price target on shares of Femasys from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th.

Femasys Stock Performance

Shares of FEMY stock opened at $1.57 on Thursday. Femasys has a one year low of $0.86 and a one year high of $2.12. The company’s 50-day moving average is $1.32 and its 200 day moving average is $1.20. The company has a market capitalization of $35.95 million, a price-to-earnings ratio of -1.94 and a beta of -2.86. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94.

Institutional Trading of Femasys

A number of institutional investors have recently made changes to their positions in FEMY. Virtu Financial LLC purchased a new position in shares of Femasys in the fourth quarter worth approximately $25,000. Aljian Capital Management LLC purchased a new position in shares of Femasys in the third quarter worth approximately $27,000. Jane Street Group LLC purchased a new position in shares of Femasys in the fourth quarter worth approximately $30,000. XTX Topco Ltd boosted its holdings in shares of Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after buying an additional 18,004 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Femasys in the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.